{"id":336495,"date":"2025-12-08T07:09:08","date_gmt":"2025-12-08T07:09:08","guid":{"rendered":"https:\/\/www.newsbeep.com\/us\/336495\/"},"modified":"2025-12-08T07:09:08","modified_gmt":"2025-12-08T07:09:08","slug":"united-states-cell-therapy-market-2033","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us\/336495\/","title":{"rendered":"United States Cell Therapy Market 2033"},"content":{"rendered":"

\"Cell<\/a><\/p>\n

Cell Therapy Market<\/p>\n

Market Size and Growth<\/p>\n

Cell Therapy Market reached US$ 6.52 Billion in 2024 and is expected to reach US$ 48.98 Billion by 2033, growing at a CAGR of 21.4% during the forecast period 2025-2033.<\/p>\n

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https:\/\/www.datamintelligence.com\/download-sample\/cell-therapy-market?sb<\/p>\n

Key Development:<\/p>\n

United States: Recent Industry Developments<\/p>\n

\u2705 In December 2025, Kite (a Gilead Sciences company) presented Phase\u20101 data for its next\u2010generation bicistronic CAR\u2010T therapies (KITE\u2010753 and KITE\u2010363) showing encouraging complete response rates and a favorable safety profile in relapsed\/refractory B\u2010cell lymphoma.<\/p>\n

\u2705 In November 2025, the global cell and gene therapy sector saw a surge in financing, partnerships and clinical\u2010trial activity underlining renewed momentum as the field transitions from early promise to broader scale development and commercialization.<\/p>\n

\u2705 In November 2025, A\u2010SEEDS Co., Ltd. (Japan\u2010based) partnered with Cell Therapies Pty Ltd. (Australia) for GMP manufacturing of A\u2010SEEDS’ lead non\u2010viral CAR\u2010T cell candidate enabling global clinical\u2010trial supply and reinforcing cross\u2010border manufacturing collaboration.<\/p>\n

\u2705 In October 2025, In\u2010vivo cell therapies and non\u2010viral \/ off\u2010the-shelf approaches are becoming bright spots in the CGT (cell & gene therapy) landscape pointing to a shift in focus toward scalable, next\u2010gen cell therapy platforms.<\/p>\n

Buy Now & Unlock 360\u00b0 Market Intelligence: https:\/\/www.datamintelligence.com\/buy-now-page?report=cell-therapy-market<\/p>\n

Japan: Recent Industry Developments<\/p>\n

\u2705 In November 2025, Teijin Limited formed a strategic alliance with BioVaram to explore expansion of regenerative medicine products and medical\u2010device usage in India and Japan signalling a push for broader adoption of cell therapy and regenerative products beyond Japan.<\/p>\n

\u2705 In November 2025, Teijin (via its CDMO arm) and Cell Therapies Pty Ltd signed a Memorandum of Understanding to strengthen regional manufacturing infrastructure for cell and gene therapies aimed at improving access and streamlining cross-border regulatory and supply\u2010chain operations.<\/p>\n

\u2705 In November 2025, A-SEEDS and Cell Therapies announced a manufacturing partnership for A-SEEDS’ novel CAR\u2010T cell therapy candidate, paving way for GMP production and planned clinical trials a concrete step toward bringing Japanese\u2010developed cell therapies into global trials.<\/p>\n

\u2705 In October 2025, it was reported that cell and gene therapy manufacturing and regulatory\u2010infrastructure development in Japan are gaining strategic attention, reflecting a broader shift toward making Japan a vital hub in CGT scale\u2010up and commercialization.<\/p>\n

Key Players: <\/p>\n

=> Gilead Sciences, Inc., Novartis AG, Vericel Corporation, CO.DON GmbH, Bristol Myers Squibb company., IOVANCE Biotherapeutics, Inc., Dendreon Pharmaceuticals LLC., Enzyvant Therapeutics GmbH., CellTrans., and Gamida Cell Inc., among others.<\/p>\n

Speak to Our Analyst and Get Customization in the report as per your requirements: https:\/\/www.datamintelligence.com\/customize\/cell-therapy-market?sb<\/p>\n

Key Segments: <\/p>\n

By Source<\/p>\n

Autologous cell therapies lead with 55% share, driven by reduced risk of immune rejection, personalized treatment approaches, and widespread adoption in oncology and musculoskeletal therapies. Allogenic sources account for 45%, supported by off-the-shelf availability, scalable production, and increasing research in immunodeficiency and Graft-versus-Host Disease (GVHD) management.<\/p>\n

By Cell Type<\/p>\n

Stem cells dominate with 65% share, fueled by applications in regenerative medicine, oncology, and musculoskeletal repair, supported by clinical trials and increasing approvals for stem cell therapies. Non-stem cells hold 35%, reflecting niche applications in immunotherapy, blood-based treatments, and targeted cellular interventions.<\/p>\n

By Application<\/p>\n

Oncology leads with 30% share, driven by cell-based immunotherapies, personalized cancer treatments, and ongoing clinical development pipelines. Musculoskeletal conditions account for 20%, supported by regenerative therapy adoption for cartilage, bone, and joint repair. Gastrointestinal (GIT) conditions represent 15%, fueled by emerging research in inflammatory bowel diseases and gut regeneration. Immunodeficiency disorders hold 10%, reflecting therapeutic applications for rare and chronic conditions. Graft-versus-host disease (GVHD) accounts for 10%, driven by allogenic cell therapy innovations. Other applications make up 15%, including autoimmune diseases, cardiovascular, and dermatological indications.<\/p>\n

By Region<\/p>\n

North America – 40% Share

\nNorth America leads with 40%, driven by advanced research infrastructure, high adoption of autologous stem cell therapies, strong regulatory support, and robust clinical trial activities in the U.S. and Canada.<\/p>\n

Europe – 25% Share

\nEurope holds 25%, supported by healthcare infrastructure, increasing investments in regenerative medicine, and adoption across Germany, U.K., France, Italy, and other key markets.<\/p>\n

Asia Pacific – 20% Share

\nAsia Pacific accounts for 20%, fueled by growing healthcare access, increasing R&D investments, and adoption of cell therapies in China, Japan, India, and Southeast Asia.<\/p>\n

South America – 7% Share

\nSouth America holds 7%, driven by rising awareness, healthcare modernization, and emerging clinical applications in Brazil, Argentina, and neighboring countries.<\/p>\n

Middle East & Africa – 8% Share

\nThe Middle East & Africa represent 8%, supported by increasing medical infrastructure, government initiatives for advanced therapies, and adoption of stem cell treatments in GCC countries, South Africa, and other regional hubs.<\/p>\n

FAQ<\/p>\n

What is the current size of the Cell Therapy Market?<\/p>\n

A: In 2024, the Cell Therapy Market was valued at US$ 6.52 Billion, reflecting its strong industry presence.<\/p>\n

Q2: How large is the Cell Therapy Market expected to be by 2033?<\/p>\n

A: By 2033, industry forecasts suggest the Cell Therapy Market will grow to around US$ 48.98 Billion , demonstrating significant expansion.<\/p>\n

Q3: What is the growth rate of the Cell Therapy Market?<\/p>\n

A: The market is projected to expand at a compound annual growth rate (CAGR) of 21.4% during the forecast period from 2025 to 2033.<\/p>\n

Unlock 360\u00b0 Market Intelligence with DataM Subscription Services: https:\/\/www.datamintelligence.com\/reports-subscription?sb<\/p>\n

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.<\/p>\n

\u2705 Competitive Landscape

\n\u2705 Sustainability Impact Analysis

\n\u2705 KOL \/ Stakeholder Insights

\n\u2705 Unmet Needs & Positioning, Pricing & Market Access Snapshots

\n\u2705 Market Volatility & Emerging Risks Analysis

\n\u2705 Quarterly Industry Report Updated

\n\u2705 Live Market & Pricing Trends

\n\u2705 Import-Export Data Monitoring<\/p>\n

Have a look at our Subscription Dashboard: https:\/\/www.youtube.com\/watch?v=x5oEiqEqTWg?sb<\/p>\n

Contact Us –<\/p>\n

Company Name: DataM Intelligence

\nContact Person: Sai Kiran

\nEmail: Sai.k@datamintelligence.com

\nPhone: +1 877 441 4866

\nWebsite: https:\/\/www.datamintelligence.com<\/p>\n

About Us –<\/p>\n

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.<\/p>\n

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.<\/p>\n

This release was published on openPR.
\n <\/p>\n","protected":false},"excerpt":{"rendered":"Cell Therapy Market Market Size and Growth Cell Therapy Market reached US$ 6.52 Billion in 2024 and is…\n","protected":false},"author":2,"featured_media":336496,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[18],"tags":[1276,23,1275,1271,3,1269,1274,1278,1277,1279,1268,1272,1270,1273,21,19,22,20,25,24],"class_list":["post-336495","post","type-post","status-publish","format-standard","has-post-thumbnail","category-united-states","tag-advertising","tag-america","tag-marketing","tag-media-release","tag-news","tag-news-release","tag-pr","tag-pr-marketing","tag-pr-service","tag-pr-strategy","tag-presses-release","tag-pressreleases","tag-public-relations","tag-publicity","tag-united-states","tag-united-states-of-america","tag-unitedstates","tag-unitedstatesofamerica","tag-us","tag-usa"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/336495","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=336495"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/336495\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/336496"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=336495"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=336495"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=336495"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}